[go: up one dir, main page]

WO2007065713B1 - UTILISATION DE 8-α-ERGOLINES POUR LE TRAITEMENT DES TROUBLES CEREBRAUX - Google Patents

UTILISATION DE 8-α-ERGOLINES POUR LE TRAITEMENT DES TROUBLES CEREBRAUX

Info

Publication number
WO2007065713B1
WO2007065713B1 PCT/EP2006/011865 EP2006011865W WO2007065713B1 WO 2007065713 B1 WO2007065713 B1 WO 2007065713B1 EP 2006011865 W EP2006011865 W EP 2006011865W WO 2007065713 B1 WO2007065713 B1 WO 2007065713B1
Authority
WO
WIPO (PCT)
Prior art keywords
cyclo
nhc
con
cooc
conh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/011865
Other languages
English (en)
Other versions
WO2007065713A3 (fr
WO2007065713A2 (fr
WO2007065713A8 (fr
Inventor
Heinz Palla
Harald Mottl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AXXONIS PHARMA GmbH
Original Assignee
AXXONIS PHARMA GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AXXONIS PHARMA GmbH filed Critical AXXONIS PHARMA GmbH
Publication of WO2007065713A2 publication Critical patent/WO2007065713A2/fr
Publication of WO2007065713A3 publication Critical patent/WO2007065713A3/fr
Publication of WO2007065713A8 publication Critical patent/WO2007065713A8/fr
Publication of WO2007065713B1 publication Critical patent/WO2007065713B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés dérivés de la 8-α-ergoline et les sels, les énantiomères, les mélanges d'énantiomères, les diastéréomères, les mélanges de diastéréomères, les hydrates, les solvates et racémates et/ou les sels pharmaceutiquement acceptables de ces composés utilisables dans des compositions pharmaceutiques avec des supports, des excipients et/ou des diluants pharmaceutiquement acceptables. Lesdits composés dérivés de la 8-α-ergoline sont utilisables pour la préparation de compositions pharmaceutiques destinées au traitement et/ou à la prophylaxie des crises d'épilepsie, de la pression crânienne accrue et de l'œdème cérébral dans la phase aiguë ou de réhabilitation d'une lésion cérébrale.
PCT/EP2006/011865 2005-12-08 2006-12-08 UTILISATION DE 8-α-ERGOLINES POUR LE TRAITEMENT DES TROUBLES CEREBRAUX Ceased WO2007065713A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05026875.4 2005-12-08
EP05026875 2005-12-08

Publications (4)

Publication Number Publication Date
WO2007065713A2 WO2007065713A2 (fr) 2007-06-14
WO2007065713A3 WO2007065713A3 (fr) 2007-08-02
WO2007065713A8 WO2007065713A8 (fr) 2007-09-07
WO2007065713B1 true WO2007065713B1 (fr) 2007-10-18

Family

ID=36177289

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/011865 Ceased WO2007065713A2 (fr) 2005-12-08 2006-12-08 UTILISATION DE 8-α-ERGOLINES POUR LE TRAITEMENT DES TROUBLES CEREBRAUX

Country Status (1)

Country Link
WO (1) WO2007065713A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902815A (en) * 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
EP1336406A1 (fr) * 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Agonistes partiels du récepteur D2 de la dopamine et inhibiteurs de la sérotonine et/ou de la noradrénaline
WO2005018541A2 (fr) * 2003-07-11 2005-03-03 Pharmacia Corporation Compositions renfermant un inhibiteur selectif de la cyclo-oxygenase-2 et un agent modulant la serotonine destinees au traitement de lesions du systeme nerveux central
GB0400802D0 (en) * 2004-01-14 2004-02-18 Daniolabs Ltd Compounds for the treatment of disease

Also Published As

Publication number Publication date
WO2007065713A3 (fr) 2007-08-02
WO2007065713A2 (fr) 2007-06-14
WO2007065713A8 (fr) 2007-09-07

Similar Documents

Publication Publication Date Title
AU2018395101B2 (en) Pyridyl imidazobenzodiazepine propionate compound and synthesis and use thereof
RU2017143609A (ru) Соединения для применения для лечения нервно-мышечных расстройств
AU2009260060B2 (en) Thiazolyl- and oxazolyl-isoquinolinones and methods for using them
US11434205B2 (en) Substituted imidazole carboxylate derivatives and the use thereof
EP3549945A1 (fr) Dérivé d'alloprégnénolone soluble dans l'eau et son utilisation
EP3828169B1 (fr) Composé dication, son procédé de préparation et son utilisation
JP2005522439A5 (fr)
US3755584A (en) Tranquilizers
FI2968346T3 (fi) Menetelmiä ja koostumuksia gamma-glutamyylisyklin muokkaamiseksi
WO2007065713B1 (fr) UTILISATION DE 8-α-ERGOLINES POUR LE TRAITEMENT DES TROUBLES CEREBRAUX
US7501416B2 (en) Quinoxaline compounds and methods of using them
FI86733B (fi) Analogifoerfarande foer framstaellning av terapeutiskt anvaendbar piperazinkarboxylsyra.
JPH0669951B2 (ja) ５ｈｔ▲下２▼受容体の選択的遮断剤
CA2557758C (fr) Composition therapeutique destinee a prevenir ou a traiter une vessie hyperactive qui accompagne un trouble nerveux
EP1511741B1 (fr) Derives ester d'un acide decahydroisoquinoline-3 carboxylique utiles en tant qu'analgesiques
EP2116236A1 (fr) Dérivés de bisbenzamidine pour une utilisation en tant qu'antioxydants
JP2010532780A (ja) 慢性疼痛の治療における酸化窒素放出化合物の使用
CN1062552C (zh) 环己二烯衍生物、含有它们的药物及其制备方法与用途
CN1490329A (zh) 咪唑啉取代的苯氧乙酰寡肽类衍生物，它们的合成及在医学中的应用
CN1093706A (zh) 旋光氨基香豆冉衍生物的晶体盐及其制备和用途
KR20110101488A (ko) 올란자핀 지나포에이트염 및 이의 용도
KR100699737B1 (ko) 신경 질환 치료제
WO2005097869A1 (fr) Polymeres comprenant des composes modulateurs de canaux ioniques et utilisations de ceux-ci
WO2006088080A1 (fr) DÉRIVÉ DE CYCLOHEPTA[b]PYRIDINE-3-CARBONYLGUANIDINE ET PRODUITS PHARMACEUTIQUES CONTENANT LEDIT DÉRIVÉ
HK40010035A (en) Water-soluble allopregnenolone derivative and use thereof

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC DATED 22.08.2008

122 Ep: pct application non-entry in european phase

Ref document number: 06829457

Country of ref document: EP

Kind code of ref document: A2